MedTrace Logo

RAS Mutations in ctDNA and Anti-EGFR reINTROduction in mCRC (RASINTRO)

NCT03259009 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 73

Last updated 2017-09-11

No results posted yet for this study

Summary

Some data have suggested a clinical survival benefit related to the reintroduction of anti-EGFRs therapy in patients with metastatic colorectal cancer (mCRC). Based on resistance mechanisms related to the development of resistant clones, the investigators could assume that patients who benefited most from the reintroduction of anti-EGFRs were those who, through interval chemotherapy, had no longer mutated RAS clone in plasma that appeared during the progression with the first anti-EGFR treatment. Conversely, those who did not benefit from this therapy were probably patients who had mutated RAS clones circulating at the time of reintroduction of anti-EGFRs. To support this hypothesis, investigators propose to evaluate the correlation between the eventual presence of RAS mutations in circulating blood and the efficacy of an anti-EGFR therapy reintroduction in patients with mCRC.

Conditions

Sponsors & Collaborators

  • Hôpital Européen George Pompidou, APHP, Paris, France

    collaborator UNKNOWN

  • UMR-S1147, Université Paris Descartes

    collaborator UNKNOWN

  • Methodology and Quality of Life in Oncology Unit, Besançon University Hospital, France

    collaborator UNKNOWN

  • Pitié-Salpêtrière Hospital

    collaborator OTHER

  • Poitiers University Hospital, Poitiers, France

    collaborator UNKNOWN

  • University Hospital Robert Debré, Reims, France

    collaborator UNKNOWN

  • Rennes University Hospital, Rennes, France

    collaborator UNKNOWN

  • Association des Gastroentérologues Oncologues

    lead OTHER

Principal Investigators

  • Aziz ZAANAN, MD, PhD · European Georges Pompidou Hospital, Paris, France

  • Julien TAIEB, MD, PhD · European Georges Pompidou Hospital, Paris, France

  • Pierre LAURENT-PUIG, MD, PhD · UMR-S1147, Université Paris Descartes, Paris, France

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-01
Primary Completion
2020-01-01
Completion
2020-06-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03259009 on ClinicalTrials.gov